Issue link: https://uberflip.scri.com/i/1521062
0529/24SCR019-14/R3 Abstract Presentation Calendar ASCO® 2024 6 Saturday Friday Sunday Monday Tuesday Publication Only SATURDAY, JUNE 1 ST 9:00am - 12:00pm Central Time (continued) Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 9:00am - 12:00pm Hall A Poster TPS3165 A phase 1/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1. Yamamoto N Patel M Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster TPS3173 Study of ELU001, a C'Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors. Ma WW Perez C, Hamilton E, Bashir B Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster TPS3191 A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor IMP1734 in participants with advanced solid tumors. Sonpavde G Falchook G, Garmezy B Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster TPS3167 An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics of VIP943 monotherapy in patients with advanced CD123+ hematologic malignancies. Strickland S Strickland S Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster TPS2670 Phase 1 study of ASP1002, a bispecific antibody targeting claudin 4 (CLDN4) and CD137, in patients with locally advanced (LA) or metastatic solid tumors that express CLDN4. Pelster M Pelster M Developmental Therapeutics— Immunotherapy 9:00am - 12:00pm Hall A Poster TPS3190 A phase 1/1b first-in-human (FIH) study of JZP898 as monotherapy and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors. McKean M McKean M, Hutson T, Spira A Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster TPS3178 An open-label study to assess the safety and efficacy of naporafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations (SEACRAFT-1). Spira A McKean M, Wang J Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster TPS3166 A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/ resistant ovarian cancer and other advanced solid tumors. Spira A Falchook G, Patel M, Richardson D, Subbiah V Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:30am - 12:00pm 11:15 - 11:30am Hall B1 Oral Presentation and Recognition of Conquer Cancer Top Donors Burris HA Opening Session